Molecular profiling guides ovarian cancer maintenance: HRD and BRCA results steer PARP inhibitors, bevacizumab choices, and patient counseling.
Erin Crane, MD, MPH
Erin Crane, MD, PhD, is a gynecologist oncologist with Atrium Health in Charlotte, NC.
Articles by Erin Crane, MD, MPH
The approved PARP inhibitor niraparib has been beneficial for patients with recurrent ovarian cancer, but new second-line restrictions for certain patients have led physicians to be more cautious when re-challenging these patients.